Literature DB >> 27651704

25 Gauge Endoresection for Moderate to Large Choroidal Melanoma.

Pradeep Venkatesh1, Varun Gogia1, Shikha Gupta1, Bhavin M Shah1.   

Abstract

Entities:  

Year:  2015        PMID： 27651704      PMCID： PMC5016320          DOI： 10.1007/s13193-015-0459-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


× No keyword cloud information.
  7 in total

1.  Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study.

Authors:  Daniela Suesskind; Anja Ulmer; Ursel Schiebel; Gerhard Fierlbeck; Bernhard Spitzer; Martin S Spitzer; Karl U Bartz-Schmidt; Salvatore Grisanti
Journal:  Acta Ophthalmol       Date:  2011-02       Impact factor: 3.761

2.  Vitreoretinal surgery and endoresection in high posterior choroidal melanomas.

Authors:  J García-Arumí; L Sararols; V Martinez; B Corcostegui
Journal:  Retina       Date:  2001       Impact factor: 4.256

3.  Endoresection of choroidal melanoma.

Authors:  B Damato; C Groenewald; J McGalliard; D Wong
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

4.  Ab interno resection of uveal melanoma.

Authors:  G A Peyman; S B Cohen
Journal:  Int Ophthalmol       Date:  1986-04       Impact factor: 2.031

5.  Internal eye wall resection for posterior uveal melanoma.

Authors:  K J Lee; G A Peyman; S Raichand
Journal:  Jpn J Ophthalmol       Date:  1993       Impact factor: 2.447

6.  Endoresection versus iodine-125 plaque brachytherapy for the treatment of choroidal melanoma.

Authors:  Josep M Caminal; Karol Mejia; Cristina Masuet-Aumatell; Lluis Arias; Josep M Piulats; Cristina Gutierrez; Joan Pera; Jaume Catala; Marc Rubio; Jordi Arruga
Journal:  Am J Ophthalmol       Date:  2013-05-13       Impact factor: 5.258

7.  Endoresection in high posterior choroidal melanomas: long-term outcome.

Authors:  J García-Arumí; M A Zapata; O Balaguer; A Fonollosa; A Boixadera; V Martinez-Castillo
Journal:  Br J Ophthalmol       Date:  2008-08       Impact factor: 4.638
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.